Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
172
resultados
Última actualización
29/09/2025 [07:29:00]
Resultados 50 a 75 de 172
Resumen de: CN120375071A
The invention relates to the field of medical image processing, and discloses a Crohn disease intestinal stenosis type identification method based on radiomics and deep learning, which comprises the following steps: marking a region of interest of an intestinal stenosis section through standardized ultrasonic gray-scale image acquisition, and extracting radiomics features and deep learning features; constructing a classification model based on image omics by using a random forest algorithm, and extracting deep features and constructing a classification model by using a ResNet50 deep learning network; in order to further improve the classification performance, in combination with the results of the radiomics model and the deep learning model, multi-modal classification is realized through weighted fusion; the classification result is used for distinguishing inflammatory stenosis and fibrous stenosis of the intestinal tract of the Crohn's disease. According to the method, the dependence of traditional ultrasonic diagnosis on experience of operators is overcome, the diagnosis consistency and accuracy are remarkably improved, and reliable support is provided for non-invasive accurate diagnosis of the Crohn disease intestinal stenosis type.
Resumen de: CN120369944A
The invention discloses a new target for predicting the curative effect of a PD-1 antibody on tumor and colitis, and belongs to the technical field of biomedicine. Based on experiments, the WD6305 is used independently to promote tumor growth, and the tumor growth speed when the WD6305 is combined with the PD-1 antibody is slower than that when the PD-1 antibody is used independently, so that the WD6305 and the PD-1 antibody have potential application value in preparation of the medicine for treating the tumor, and the application prospect is broad. Meanwhile, experiments show that METTL14 is a new target for predicting the curative effect of the PD-1 antibody on tumor and colitis.
Resumen de: CN120369664A
The invention belongs to the field of biological medicines, and particularly discloses an identification method of honeysuckle flower polysaccharide and application of the honeysuckle flower polysaccharide in preparation of medicines for preventing or treating inflammatory bowel diseases. A DSS solution is used for inducing a mouse inflammatory bowel disease model, honeysuckle polysaccharide FLP is used for gavage treatment, and mouse weight, disease activity indexes, colorectal tissue pathological structures, spleen pathological structures, HE staining, intestinal microbial structures, intestinal metabolite spectrums and the like are detected and analyzed. Results show that the honeysuckle flower polysaccharide can delay inflammatory bowel diseases of model animals in an oral administration manner, and has the characteristics of high targeting property, convenience in administration and the like. Good application prospects are realized in the aspect of treating the inflammatory bowel disease.
Resumen de: CN116514983A
The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody and application thereof. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano antibody sequence, and finally separating to obtain three nano antibodies which are respectively named A2, A6 and H10. The three nano antibodies have different antigen complementarity determining regions, SPR results show that the three nano antibodies all show high-affinity binding with human DR3 extracellular domains, and the nano antibodies provided by the invention are expected to provide experimental factual basis for treatment thinking of DR3-related diseases.
Resumen de: WO2025155794A1
The present inventive concept provides a subject's fecal protein bioprofile and methods for establishing the same. Also provided are methods of determining a subject's risk for developing an inflammatory disorder, a neurological disorder, a neurodegenerative disorder, or a disorder associated with aging or monitoring the same. The inventive concept further provides kits for use in the methods described herein.
Resumen de: WO2025155566A1
An MIS beveled driver and methods are provided for implanting beveled IBS bone compression and fully threaded screws to encourage bone fusion. The driver includes an elongated driver shaft extending from a shaped distal end to a proximal handle, a beveled sleeve having an angled distal-most surface adjacent to the shaped distal end that couples with the bone screw, and beveled marks on the driver shaft to indicate an orientation of the sleeve. The sleeve is affixed to the driver shaft such that the angle of the distal-most surface remains aligned with the beveled marks. The sleeve ensures that the bone screw only assembles with the driver in an orientation that enables aligning a proximal head portion of the bone screw to be flush with the surrounding bone surface. The sleeve includes a radio marker to enable observation of the bone screw by way of fluoroscopy.
Resumen de: WO2025152918A1
Provided in the present invention are humanized anti-human CD132 monoclonal antibodies and the use thereof. The present invention performs humanized transformation on the basis of monoclonal chimeras 2D4 and 5H10, so as to obtain high-affinity humanized monoclonal antibodies h2D4H4K12 and h5H10H6K4 targeting the human CD132 by means of screening; therefore, without attenuating the antibody activity, the immunogenicity of parental chimeras is reduced, thus reducing the possible risk that medicated patients may generate immune responses on the antibodies. The monoclonal antibodies can be used for prevention, neutralization or treatment of autoimmune diseases related to IL-4, IL-7, IL-9, IL-15 and/or IL-21 cytokines, e.g. systemic lupus erythematosus, rheumatoid arthritis, vitiligo, psoriasis, alopecia areata, inflammatory bowel disease, systemic sclerosis, graft-versus-host disease and aplastic anemia.
Resumen de: US2025237648A1
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.
Resumen de: US2025237665A1
A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohn's disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohn's disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: CN119546632A
The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.
Resumen de: CN120329225A
The invention relates to the technical field of biology, in particular to isoconic acid and analogues thereof, a preparation method of the isoconic acid and the analogues thereof and application of the isoconic acid and the analogues in diagnosis and treatment of inflammation-related diseases. The invention finds that isoconic acid as an inflammation biomarker and a novel metabolite with an anti-inflammatory effect has a relatively strong inhibition effect on M1 polarization of human and mouse macrophages induced by lipopolysaccharide (LPS); the LPS-induced mouse inflammation model has the effects of prolonging the survival time and relieving inflammation phenotypes of tissues such as brain, spleen and liver; the anti-inflammatory effects of expression, secretion and the like of inflammatory factors are reduced. The composition has the effects of reducing adipose tissue inflammatory factors and relieving weight gain in a high-fat diet inflammation model; in a mouse inflammatory bowel disease model, the compound has the effects of increasing the length and reducing steel research pathological scores and inflammatory factors. Therefore, the isoconic acid can be used for diagnosing and treating inflammatory diseases, such as septicopyemia, inflammatory bowel disease, neuroinflammation, inflammation caused by high fat diet and the like.
Resumen de: CN120330323A
The invention discloses an intestinal flora marker related to a children inflammatory bowel disease, a product and application of the intestinal flora marker. The intestinal flora marker disclosed by the invention is one or more of streptococcus salivarius, bacteroides ovatus, bacteroides vulgaris, clostridium altaicum, actinomycetes decayed tooth and clostridium difficile, and can be applied to prediction and diagnosis of patients with the inflammatory bowel disease in children, the diagnosis process is completely noninvasive, and the accuracy is high.
Resumen de: US2025230505A1
Disclosed herein are methods, kits and compositions for treating an inflammatory disease. These methods, kits and compositions may be particularly useful for subjects carrying a risk genotype and/or expressing a transcriptomic risk signature that is indicative of severe inflammatory disease phenotypes for which existing treatment options are limited.
Resumen de: CN120309604A
The invention discloses a diagnosis and treatment prodrug based on inflammatory disease activation and a preparation method and application thereof, and belongs to the technical field of biological medicine. The diagnosis and treatment prodrug disclosed by the invention not only can realize accurate diagnosis on an inflammatory part through NIR fluorescence imaging, but also can selectively release ozanimod in an inflammatory tissue to play a role in efficiently treating colitis, so that the toxicity to normal tissues is reduced. Diagnosis and treatment prodrug with structure as shown in general formula I: # imgabs0 #
Resumen de: CN120299684A
The invention discloses an intelligent diagnosis system and method for Crohn disease muscular layer change, and belongs to the technical field of medical image analysis and artificial intelligence, and the system comprises an image collection and processing module which is used for receiving an MRI image of a patient, carrying out the de-noising and enhanced comparison, providing high-quality image data for the subsequent scoring analysis, and carrying out the calculation of the image data based on a preset algorithm, automatically sketching a target area; the image feature extraction module is used for extracting 102 radiomics features from the T1 enhanced image by using a Pyradiomics tool, and combining DCE-MRI functional parameters and conventional magnetic resonance parameters; the clinical data integration module is used for integrating clinical indexes of patients and constructing a multi-dimensional feature pool; and the score calculation module is used for calculating the extracted features. According to the intelligent diagnosis system and method for the Crohn disease muscular layer change, scientific research development can be promoted, an innovative muscular layer change evaluation scheme provides reliable data support for further scientific research, and the research progress in the field can be promoted.
Resumen de: US2025223626A1
The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacterium, or hydrogen sulfide.
Resumen de: EP4582099A2
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
Resumen de: CN120267829A
The invention provides an application of a substance for up-regulating the expression level of at least one biomarker in a signal channel of a protease activated receptor 2 (PAR2)-mediated lysosome function in preparation of a composition for one or more of the following: (1) regulating lysosome acidification in a cell; (2) regulating the autophagy function in the cells; (3) regulating autophagosome-lysosome fusion in the cells; (4) the accumulation of reactive oxygen species (ROS) in cells is reduced; (5) reducing the DNA damage level in the cells; (6) reducing the expression level of inflammatory factors in cells; (7) improving or treating acute injury of colitis in the subject; (8) improving or treating the inflammatory bowel disease of the subject; (9) preventing, ameliorating or treating inflammatory cancer transformation in a subject; and (10) preventing, ameliorating or treating colorectal cancer in the subject; wherein the biomarker is selected from PAR2 (Protein Activated Receptor 2), FOXA2 (Forkhead Frame Protein A2) and a lysosome V-type proton pump subunit ATP6V0E1.
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: CN120254102A
The invention provides a quality control method of an effective component of alhagi sparsifolia for treating ulcerative colitis and application of the quality control method, and the method comprises the following steps: characterizing the material composition of the effective component of alhagi sparsifolia by using an ultra-high performance liquid chromatography-mass spectrometry technology, and determining key active components by combining network pharmacology prediction and topological analysis; the quality internal control method for the effective components of the alhagi sparsifolia for treating the ulcerative colitis is constructed by adopting a high performance liquid chromatography technology and a thin-layer chromatography technology, the material information of the effective components of the alhagi sparsifolia can be comprehensively reflected, the quality of the effective components of the alhagi sparsifolia in different batches can be effectively monitored, and the method is high in precision, good in reproducibility and suitable for industrial production. The method can be used for controlling the quality of the effective components of the alhagi sparsifolia for treating ulcerative colitis, and provides a basis for solving the problem that the existing standard cannot comprehensively and systematically analyze the material composition and content control of the effective components of the alhagi sparsifolia.
Resumen de: CN120254292A
The invention provides a marker combination for predicting recurrence of ulcerative colitis and application thereof, and particularly, the marker is at least one of SLC6A14, MUC-2 and Nanncy index. The marker can be used for diagnosis and recurrence prediction of ulcerative colitis, and especially has relatively strong detection capability for relieving and recurrence conditions of patients after clinical drug treatment.
Resumen de: CN120254281A
The invention relates to application of an intestinal mucosa inflammation serum marker in preparation of a diagnosis and treatment product for treating the intestinal mucosa inflammation state of a patient suffering from Crohn disease and predicting the treatment effect of infliximab, and belongs to the technical field of biological medicine, and the intestinal mucosa inflammation serum marker is matrix remodeling related 5 protein (MXRA5). When the matrix remodeling related 5 protein (MXRA5) is used as a target spot for serum protein detection, high sensitivity and specificity are achieved, and therefore the MXRA5 protein can be used as a screening target spot for predicting the intestinal mucosa inflammation state of a patient suffering from the Crohn disease and the treatment effect of the infliximab.
Resumen de: CN120249471A
The invention relates to the field of biological medicine, and particularly provides application of a membrane protein CMTM3 as a drug target for treating inflammatory bowel disease and related colorectal cancer. The invention discovers and verifies that deletion of Cmtm3 can protect mice from AOM/DSS induced colorectal cancer (CAC) for the first time. A further research result proves that the endothelial cell-derived CMTM3 promotes the development of enteritis. The Cmtm3 gene knockout and the imatinimex can regulate the vascular permeability in a targeted manner and have a considerable curative effect. The application also discloses that the CMTM3 promotes vascular permeability to aggravate enteritis by stabilizing CLTC and increasing gridding protein mediated endocytosis of VE-cadherin in endothelial cells, thereby promoting the development of inflammation-related colon cancer, which indicates that the CMTM3 can be used as a potential therapeutic target for enteritis and colon cancer (CAC).
Resumen de: US2025213709A1
The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.
Nº publicación: WO2025141157A1 03/07/2025
Solicitante:
HAHN SCHICKARD GES FUER ANGEWANDTE FORSCHUNG E V [DE]
HAHN-SCHICKARD-GESELLSCHAFT F\u00DCR ANGEWANDTE FORSCHUNG E. V
Resumen de: WO2025141157A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (AI) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the AI is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC- features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
BOPI
Sede Electrónica
